Literature DB >> 1382018

Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

P A Todd1, D Faulds.   

Abstract

Felodipine is a vascular-selective, dihydropyridine calcium antagonist previously investigated as a conventional tablet formulation administered twice daily. More recently considerable experience has been gained with an extended release (ER) formulation which has the convenience of once daily administration. Felodipine ER has been well studied in patients with essential hypertension. As monotherapy in mild to moderate essential hypertension, felodipine ER is at least as effective in reducing blood pressure as other calcium antagonists, beta-blockers, diuretics and ACE inhibitors, with some results favouring felodipine ER at a statistically significant level at the dosages used. It is also effective combined with controlled release metoprolol or enalapril in patients with mild to moderate essential hypertension. In patients with more severe forms of essential hypertension uncontrolled by beta-blocker and/or diuretic therapy, felodipine ER was effective as an 'add-on' therapy in placebo-controlled trials, and, at the dosages used, more effective than either sustained release nifedipine or nitrendipine. Felodipine produces effective control of blood pressure without negative effects on cardiac performance. In addition to its antihypertensive action, results suggest that felodipine therapy is associated with significant regression of left ventricular hypertrophy. Furthermore, it appears suitable for use in patients with concomitant diabetes, renal dysfunction or asthma, and is also being investigated for use in patients with congestive heart failure or angina pectoris. Felodipine ER is an effective drug for the treatment of all grades of essential hypertension, and can be used both as monotherapy and in combination with other antihypertensive agents. Further clinical experience should fully establish the long term tolerability of felodipine ER and consequently its place in therapy relative to other accepted antihypertensive drugs. However, with the convenience of once daily administration, felodipine ER is a worthwhile innovation in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382018     DOI: 10.2165/00003495-199244020-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  103 in total

1.  The effects of felodipine on the pharmacokinetics of diazepam.

Authors:  B H Meyer; F O Müller; H K Hundt; H G Luus; N de la Rey; H J Röthig
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1992-04

2.  Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension.

Authors:  W Koenig; L Binner; F Gabrielsen; M Sund; J Rosenthal; V Hombach
Journal:  J Cardiovasc Pharmacol       Date:  1991-09       Impact factor: 3.105

3.  Acute effects on exercise tolerance of felodipine and diltiazem, alone and in combination, in stable effort angina.

Authors:  P D Pucci; G Pollavini; M Zerauscheck; P Fazzini
Journal:  Eur Heart J       Date:  1991-01       Impact factor: 29.983

4.  Long-term treatment of hypertension with felodipine.

Authors:  G Flygt
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

5.  Felodipine-ER once daily as monotherapy in hypertension.

Authors:  L M Campbell; K J Cowen; F R Cranfield; J R Goves; D F Jones; C T Lees; P D Richardson; J A Teal; S J Timerick
Journal:  J Cardiovasc Pharmacol       Date:  1990-04       Impact factor: 3.105

6.  Felodipine extended-release tablets once daily are equivalent to plain tablets twice daily in treating hypertension. Dutch Hospital Multicentre Group.

Authors:  W Hart; B Westberg
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

Review 7.  Does a reduction in left ventricular hypertrophy reduce cardiovascular morbidity and mortality?

Authors:  F H Messerli; F Soria
Journal:  Drugs       Date:  1992       Impact factor: 9.546

8.  Felodipine reduces the absorption of theophylline in man.

Authors:  T Bratel; B Billing; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  A dose-finding, placebo-controlled study on extended-release felodipine once daily in treatment of hypertension.

Authors:  L M Cambell; J R Ross; J R Goves; C T Lees; A McCullagh; P Barnes; S J Timerick; P D Richardson
Journal:  J Cardiovasc Pharmacol       Date:  1989-12       Impact factor: 3.105

10.  Effects of felodipine on natriuresis, atrial natriuretic factor, the renin-angiotensin-aldosterone system, and blood pressure in essential hypertension.

Authors:  G Cerasola; S Cottone; M T Mangano; G D'Ignoto; A Pinto; M B Carone
Journal:  Clin Ther       Date:  1988       Impact factor: 3.393

View more
  16 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

Review 2.  Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.

Authors:  Risto S Cvetković; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms.

Authors:  Ibra S Fancher; Israel Rubinstein; Irena Levitan
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

Review 4.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

Review 5.  Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol.

Authors:  M J Kendall
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 6.  Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.

Authors:  M Haria; G L Plosker; A Markham
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

7.  Effects of low-dose treatment with felodipine versus fosinopril in Chinese patients with nonischemic heart failure and normal blood pressure: A double-blind, randomized, crossover study.

Authors:  Mei-Shu Lin; K Arnold Chan; Chih-Hao Wang; Nen-Chang Chang
Journal:  Curr Ther Res Clin Exp       Date:  2004-03

8.  A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension.

Authors:  I Moncica; P I Oh; I ul Qamar; D Scolnik; G S Arbus; D Hebert; J W Balfe; G Koren
Journal:  Arch Dis Child       Date:  1995-08       Impact factor: 3.791

Review 9.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

Review 10.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.